MedTrace Logo

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With "Wearing Off" Motor Fluctuations and "On" Period Dyskinesias

NCT01172379 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2014-08-22

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety, tolerability and efficacy of E2007 in Parkinson's Disease patients who have "wearing off" motor fluctuations and "on" period dyskenisias.

Conditions

Interventions

DRUG

E2007

Experimental 1 Drug: E2007 0.5 mg 1 tablet per day

DRUG

E2007

Experimental 2 Drug: E2007 1.0 mg 1 tablet per day

DRUG

E2007

Drug: E2007 2.0 mg 1 tablet per day

OTHER

Placebo Comparator

Placebo 1 tablet per day

Sponsors & Collaborators

  • Eisai Limited

    lead INDUSTRY

Principal Investigators

  • Jonathan Webster · Eisai Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2005-02-28

Countries

  • Czechia
  • France
  • Germany
  • Italy
  • Serbia
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01172379 on ClinicalTrials.gov